Drug Profile
Peramivir - BioCryst Pharmaceuticals
Alternative Names: ALPIVAB; BCX-1812; JNJ-2; PeramiFlu; Peramivir injection - BioCryst Pharmaceuticals; Rapiacta; Rapivab; RWJ-270201Latest Information Update: 04 Jan 2024
Price :
$50
*
At a glance
- Originator University of Alabama
- Developer BioCryst Pharmaceuticals; GC Biopharma; Seqirus; Shionogi
- Class Acetamides; Antivirals; Carboxylic acids; Cyclopentanes; Guanidines; Small molecules
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Influenza A virus H1N1 subtype; Influenza virus infections
Most Recent Events
- 04 Jan 2024 No development reported - Phase-III for Influenza virus infections (In adolescents, In children, In infants) in South Africa (IV)
- 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
- 30 Nov 2022 9375182- No update